Upstream Bio (NASDAQ:UPB) Coverage Initiated by Analysts at Lifesci Capital

Equities research analysts at Lifesci Capital began coverage on shares of Upstream Bio (NASDAQ:UPB) in a report issued on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $43.00 price target on the stock. Lifesci Capital’s price objective would suggest a potential upside of 48.38% from the stock’s previous close.

Several other brokerages also recently commented on UPB. Truist Financial assumed coverage on shares of Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Finally, Evercore ISI assumed coverage on shares of Upstream Bio in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.33.

Upstream Bio Trading Up 1.3%

NASDAQ:UPB opened at $28.98 on Tuesday. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $33.00. The stock has a 50-day moving average price of $22.58 and a two-hundred day moving average price of $16.77. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -15.41 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.65 million. Sell-side analysts forecast that Upstream Bio will post -4.3 earnings per share for the current year.

Institutional Trading of Upstream Bio

Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in Upstream Bio in the first quarter valued at $78,000. Nuveen LLC acquired a new position in shares of Upstream Bio during the 1st quarter worth about $138,000. Velan Capital Investment Management LP bought a new position in shares of Upstream Bio in the 1st quarter valued at about $655,000. ADAR1 Capital Management LLC acquired a new stake in shares of Upstream Bio in the first quarter valued at about $92,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Upstream Bio in the first quarter valued at about $115,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.